Lenz Therapeutics Announces FDA Approval of Vizz for the Treatment of Presbyopia - Takeaways - MDSpire

Lenz Therapeutics Announces FDA Approval of Vizz for the Treatment of Presbyopia

Near vision improvements were demonstrated within 30 minutes and lasted up to 10 hours in clinical trials.

  • July 8, 2025

  • 2 min

Share

  • 1

    Lenz Therapeutics received FDA approval for Vizz, an eye drop solution for treating presbyopia in adults.

  • 2

    Vizz improves near vision within 30 minutes and effects last up to 10 hours.

  • 3

    The treatment works by contracting the iris sphincter muscle to create a pinhole effect, enhancing depth of focus.

  • 4

    Clinical trials CLARITY 1, 2, and 3 demonstrated Vizz's safety and efficacy with mild, transient adverse events.

  • 5

    Commercial availability of Vizz is expected by mid-Q4 2025, with samples anticipated as early as October 2025.

Original Source(s)

Lenz Therapeutics Announces FDA Approval of Vizz for the Treatment of Presbyopia

  • July 8, 2025

Related Content

Presbyopia Drops, a Promising Solution

While over-the-counter, prescription corrective lenses, and surgical interventions have been the mainstays of presbyopia management, presbyopia drops offer a non-invasive alternative.

Refraction Pearls for the Early Presbyope

Dr. Habibi's clinical and patient counseling suggestions.

Navigating Presbyopia Conversations With Confidence

Understanding the concept of ocular maturity helps staff frame presbyopia as a natural, manageable process with modern solutions.